Researchers have accumulated consistent evidence over decades that people with lower blood vitamin D (25‑hydroxyvitamin D, 25[OH]D) face a higher risk of developing multiple sclerosis (MS) and that lower levels correlate with more MRI activity and relapses in established disease. This is not only correlation: newer genetic (Mendelian randomization) analyses support a causal link—people genetically predisposed to lower vitamin D have higher MS risk. Post‑hoc analyses of large clinical trial cohorts (notably BENEFIT and BEYOND) also found that higher 25(OH)D predicted fewer new MRI lesions and slower progression (see BENEFIT data summarized in the source review).
What does this means for practitioners? As clinicians you work upstream: prevention, immune balance, pregnancy care, lifestyle, and safe supplementation. Vitamin D is a modifiable, low‑cost factor with a favorable safety profile when used thoughtfully — making it a practical addition to your preventive and supportive toolkit.
Here are the highlights and need-to-know findings from “Vitamin D and Multiple Sclerosis: A Comprehensive Review,” a study published in Neurology and Therapy Journal:
Key Practical Takeaways
- Risk and activity correlate with 25(OH)D levels: multiple cohort studies show stepwise reductions in relapse and MRI activity as 25(OH)D rises. Some analyses suggest the clearest benefits appear when levels approach 100 nmol/L (40 ng/mL). (See EPIC, BENEFIT, BEYOND summaries in the review.)
- Causality is plausible: Mendelian randomization studies argue low vitamin D contributes to MS risk rather than just being a consequence.
- Supplementation shows promise but evidence is mixed: smaller RCTs and open trials show MRI improvements and immune modulation; many trials are underpowered for clinical outcomes. Larger trials (EVIDIMS, VIDAMS) are underway/ongoing.
- Vitamin D and conventional therapy may interact beneficially: observational data suggest interferon therapy’s effects are stronger when vitamin D is adequate; some cohorts saw additive benefits for MRI outcomes.
Target ranges and testing
- Test serum 25(OH)D (the standard). Because assays vary, treat values as a guideline, not an absolute.
- Sensible target for people at MS risk or with early disease: many investigators use 75–100 nmol/L (30–40 ng/mL) as a minimum target; several studies reported lowest MRI activity above ~100 nmol/L. The Institute of Medicine’s 50 nmol/L (20 ng/mL) threshold prevents rickets but is likely insufficient from an immune perspective.
- For general prevention and immune‑support, aim for at least 75 nmol/L (30 ng/mL); consider 80–100 nmol/L (32–40 ng/mL) for higher‑risk patients while monitoring.
Dosing and safety
- Preferred form: vitamin D3 (cholecalciferol) is more potent and longer‑lasting than D2.
- Typical maintenance dosing: many practitioners use 1000–4000 IU/day to achieve and maintain 25(OH)D in the 75–100 nmol/L range; individual needs vary by baseline level, BMI, skin tone, latitude, and sun exposure.
- Loading regimens: for deficiency, short higher dosing can be used but monitor 25(OH)D and calcium. Frequent large boluses are avoidable — steady daily or weekly dosing is more physiologic.
- Safety: vitamin D toxicity is rare. Intoxication has been reported only with prolonged very high intakes (tens of thousands IU/day) or prescribing errors. Monitor serum calcium and 25(OH)D when using higher doses (>4000–6000 IU/day) or in patients with granulomatous disease, certain lymphomas, or renal impairment.
- Check levels after 8–12 weeks following dose changes, then every 3–6 months until stable, then every 6–12 months.
Special populations and clinical pearls
- Pregnancy: cohort data (Finnish maternity study) linked low maternal 25(OH)D to higher MS risk in offspring. Consider ensuring adequate maternal vitamin D per pregnancy guidance (coordinate with obstetric care).
- High BMI: adiposity lowers bioavailable vitamin D — obese patients often require higher doses to reach targets.
- Sun exposure: counsel balanced sun exposure where appropriate; intentional sun practices can support levels but are not a substitute for targeted supplementation in high‑risk or deficient patients.
- Combining with other supportive measures: vitamin D works best as part of a broader lifestyle plan (anti‑inflammatory diet, stress reduction, sleep, microbiome support, gentle exercise).
Bottom line? Test 25(OH)D routinely in patients at risk for autoimmunity, in pregnancy planning, and in people with MS. Aim for mid‑range sufficiency (commonly 75–100 nmol/L), use vitamin D3, personalize dosing, monitor safely, and integrate with broader lifestyle and immune‑support strategies. This practical approach respects the evidence to date and fits well within a prevention‑focused practice.
→ Download the FULL TEXT here.
Reference
Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurol Ther. 2018 Jun;7(1):59-85. doi: 10.1007/s40120-017-0086-4. Epub 2017 Dec 14. PMID: 29243029; PMCID: PMC5990512.
